FDA 483 - SOFTAP INC - December 11, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of SOFTAP INC, a relabeler in Livermore, CA, revealed seven significant observations concerning its quality system and manufacturing controls. The firm lacked essential written procedures for quality unit responsibilities, product distribution, complaint handling, and employee training, indicating a severe absence of cGMP compliance. These deficiencies raise serious concerns about the quality, safety, and traceability of the drug products Minnerva II and Blockaid that the firm relabels and distributes.
ID · e5a5f51c-cd9f-4ec8-8390-e2e2b89bd449